This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Evergreen Tree of ETFs to Lighten Your Christmas
by Sweta Killa
The Christmas tree of top-ranked ETFs to brighten 2021 is now ready for investors. May it spread cheer!
5 Bank Stocks Set to Rebound With Vaccine-Driven Economic Recovery
by Radhika Saraogi
Improving lending scenarios and restoration of normal activities in 2021, with the help of coronavirus vaccines rollout, will likely help banks like JPMorgan (JPM), Bank of Hawaii (BOH), Bank OZK (OZK), UMB Financial (UMBF) and Synovus (SNV) witness a rebound.
3 Airlines Stocks to Gain as the Economy Looks to Fully Reopen
by Zacks Equity Research
Rollout of the vaccine along with an expected fiscal stimulus is sure to boost the airlines industry, making it prudent to watch out for names like Mesa Air Group (MESA) and Spirit Airlines (SAVE).
Small-Caps at Record Highs Ahead of Christmas
by Mark Vickery
The small-cap Russell 2000 index has hit another closing record high today -- the 13th time this has occurred this year.
5 Best-Performing Leveraged ETFs of Fourth Quarter
by Sweta Killa
We highlight some leveraged ETFs that gained more than 85% over the past three months.
Biotech Stock Roundup: PFE/BNTX Vaccine Authorized in Europe, Updates From AMGN, & More
by Zacks Equity Research
Coronavirus vaccine updates from Moderna (MRNA) and Pfizer (PFE)/BioNTech (BNTX) continue to take centerstage in the biotech sector.
Vertex (VRTX) Inks Deal with Skyhawk for Serious Diseases
by Zacks Equity Research
Vertex (VRTX) signs a licensing agreement with privately held company Skyhawk Therapeutics to discover novel small molecules that modulate RNA splicing for treating serious diseases.
4 MedTech Stocks Up More Than 100% in 2020 With Room to Run
by Urmimala Biswas
We discuss four MedTech stocks, CDNA, FLGT, OMI and QDEL that more than doubled in 2020, and are poised to maintain market beating momentum in 2021 on strong fundamentals.
How Effective Will Vaccines be Against New Coronavirus Strain?
by Indrajit Bandyopadhyay
Pfizer (PFE) and Moderna (MRNA), the companies whose coronavirus vaccines have been approved for emergency use, are evaluating their vaccines against the fast-spreading new strain of coronavirus found in the United Kingdom.
5 High Beta & Momentum ETFs to Tap the Santa Rally
by Sweta Killa
These ETFs are expected to outperform in the seven-day period and are intriguing choices for a short spell.
4 Restaurant Stocks to Play a Likely Turnaround in 2021
by Mrithunjoy Kaushik
Although the restaurant industry is grappling with the coronavirus outbreak, restaurant stocks like JACK, RUTH, FAT and STKS have impressive 2021 earnings growth projections.
Forget Sector Rotation: Tech ETFs to Rule in Christmas Week
by Sanghamitra Saha
News of new virus strain in the UK will likely keep the market subdued this week and brighten the appeal for tech ETFs.
Pfizer/BioNTech COVID-19 Vaccine Gets Authorization in Europe
by Zacks Equity Research
Pfizer (PFE)/BioNTech's (BNTX) COVID-19 vaccine candidate is the first COVID-19 vaccine to be granted conditional authorization in Europe.
More New Highs for Stocks With Fiscal Stimulus Looking Imminent
by David Borun
Even with rising Covid-19 cases, a deal in Washington and the vaccine rollout keep investors in a buying mood.
5 Small-Cap ETFs Set to Explode on COVID-19 Vaccines
by Sweta Killa
As the economy seems on track for strong growth, a small-cap rally is expected to strengthen in the New Year.
Christmas Week Begins With Pre-market Sell-off
by Zacks Equity Research
Christmas Week Begins With Pre-market Sell-off
Pre-Markets Down to Start Christmas Week
by Mark Vickery
Though already off the lows we saw a couple hours before today's opening bell, the Dow is down 400 points, the S&P 500 -55 and the Nasdaq -140.
Moderna (MRNA) Gets FDA Emergency Use Nod for COVID-19 Vaccine
by Zacks Equity Research
Moderna (MRNA) gets emergency use authorization for coronavirus vaccine, mRNA-1273, for use in adults in the United States.
5 Biotech Stocks That More Than Doubled This Year
by Ekta Bagri
The biotech sector has been in focus through 2020 as companies like Moderna (MRNA) strive hard to develop a vaccine for COVID-19.
4 Restaurant Stocks to Watch as Vaccine Rollout Begins
by Zacks Equity Research
Vaccine rollout should allow dine-in to resume in restaurants with online delivery expected to sustain, making it prudent to keep an eye on names like Brinker International (EAT) and McDonald's (MCD)
Vaccines to Fuel Santa Claus Rally: 5 Stock Picks
by Sweta Killa
With only eight trading days left this year, markets are bracing for the so-called Santa Claus rally.
Moderna's (MRNA) COVID-19 Vaccine Gets FDA Panel's Backing
by Zacks Equity Research
An FDA panel recommends granting approval for emergency use to Moderna's (MRNA) coronavirus vaccine candidate.
J&J (JNJ) Coronavirus Vaccine Candidate Study Fully Enrolled
by Zacks Equity Research
Johnson & Johnson (JNJ) phase III study on its experimental COVID-19 single-dose vaccine candidate is now fully enrolled.
7 Nasdaq Stocks That Helped QQQ ETF Score Big in 2020
by Sanghamitra Saha
Technology stocks and ETFs have been star performers this year and made the tech-heavy index Nasdaq a winner.
FDA Approves Second COVID-19 Vaccine
by Zacks Equity Research
FDA Approves Second COVID-19 Vaccine.